Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real-World Experience

Mantle cell lymphoma is a type of B-cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation in the outcomes. In a retrospective cohort of new diagnostic Mantle Cell Lymphoma between 2010 and 2024, we identified main characteristics at diagnosis and the influence of MIPI score and ASCT. We followed patients until progression or death and compared progression-free survival and overall survival. We included 139 patients; the median age was 64 years. For patients classified as low risk according to the MIPI score, the 36-month OS rate was 79.7% (95% CI: 68%-93.5%). Intermediate risk 51.5% (95% CI: 38.2%-69.4%). And High-risk 40.4% (95% CI: 26.9%-59.5%) (p < 0.001). In the group that underwent ASCT, the 36-month OS rate was 75.2% (95% CI: 60.1%-94.6%), and in the non-transplanted group was 49% (95% CI: 39.5%-60.7%), HR 0.38 (95% CI; 019-0.74) (p = 0.002). High-risk patients and those who were not transplanted had the lowest survival compared to the other categories. These findings underscore the need for risk stratification, and effective treatment strategies, including the HSCT patient population in Colombia.